StocksFundsScreenerSectorsWatchlists
INCY

INCY - Incyte Corp Stock Price, Fair Value and News

52.81USD+0.09 (+0.17%)Market Closed

Market Summary

INCY
USD52.81+0.09
Market Closed
0.17%

INCY Stock Price

View Fullscreen

INCY RSI Chart

INCY Valuation

Market Cap

11.9B

Price/Earnings (Trailing)

19.84

Price/Sales (Trailing)

3.21

EV/EBITDA

9.4

Price/Free Cashflow

23.88

INCY Price/Sales (Trailing)

INCY Profitability

Operating Margin

93.10%

EBT Margin

22.57%

Return on Equity

11.51%

Return on Assets

8.81%

Free Cashflow Yield

4.19%

INCY Fundamentals

INCY Revenue

Revenue (TTM)

3.7B

Rev. Growth (Yr)

9.35%

Rev. Growth (Qtr)

10.26%

INCY Earnings

Earnings (TTM)

597.6M

Earnings Growth (Yr)

606.51%

Earnings Growth (Qtr)

17.41%

Breaking Down INCY Revenue

Last 7 days

-3.8%

Last 30 days

-9.5%

Last 90 days

-14.1%

Trailing 12 Months

-28.4%

How does INCY drawdown profile look like?

INCY Financial Health

Current Ratio

3.75

Debt/Equity

0

Debt/Cashflow

27.46

INCY Investor Care

Shares Dilution (1Y)

0.70%

Diluted EPS (TTM)

2.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.5B3.5B3.6B3.7B
20223.1B3.3B3.3B3.4B
20212.7B2.7B2.9B3.0B
20202.2B2.4B2.5B2.7B
20192.0B2.0B2.1B2.2B
20181.5B1.7B1.8B1.9B
20171.2B1.3B1.4B1.5B
2016857.9M941.2M1.0B1.1B
2015581.0M644.4M633.8M753.8M
2014373.7M371.6M484.6M511.5M
2013332.0M347.1M371.7M354.9M
201298.7M168.4M212.1M297.1M
2011184.6M151.5M151.4M94.5M
201049.4M89.6M129.7M169.9M
20090009.3M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Incyte Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 28, 2024
baker bros. advisors lp
acquired
-
-
1,086
-
Mar 28, 2024
clancy paul j
acquired
22,958
56.97
403
-
Mar 28, 2024
harrigan edmund
acquired
23,528
56.97
413
-
Mar 25, 2024
trotta matteo
acquired
-
-
7,828
evp, gm, dermatology us
Feb 14, 2024
hoppenot herve
acquired
-
-
41,577
chairman / ceo
Feb 14, 2024
stamoulis christiana
acquired
-
-
7,377
evp & chief financial officer
Feb 14, 2024
swain paula j
acquired
-
-
7,377
evp, human resources
Feb 14, 2024
flannelly barry p
acquired
-
-
7,377
evp & general manager us
Feb 14, 2024
stein steven h
acquired
-
-
7,377
evp & chief medical officer
Feb 14, 2024
iyengar vijay k
acquired
-
-
7,377
evp, gmapps

1–10 of 50

Which funds bought or sold INCY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 17, 2024
GRIMES & COMPANY, INC.
added
91.3
4,469,500
10,544,700
0.32%
Apr 17, 2024
NEW MEXICO EDUCATIONAL RETIREMENT BOARD
added
13.47
264,000
870,000
0.03%
Apr 17, 2024
DUMONT & BLAKE INVESTMENT ADVISORS LLC
new
-
527,770
527,770
0.15%
Apr 17, 2024
Hennion & Walsh Asset Management, Inc.
added
43.37
319,063
1,379,590
0.07%
Apr 17, 2024
HARTFORD INVESTMENT MANAGEMENT CO
reduced
-4.42
-104,562
683,013
0.02%
Apr 16, 2024
180 WEALTH ADVISORS, LLC
added
4.47
-27,047
271,405
0.05%
Apr 16, 2024
Berger Financial Group, Inc
sold off
-100
-3,796,790
-
-%
Apr 15, 2024
NorthCrest Asset Manangement, LLC
reduced
-8.33
-76,115
376,287
0.01%
Apr 15, 2024
Davis Investment Partners, LLC
reduced
-7.05
-198,202
655,215
0.29%
Apr 15, 2024
Wealth Alliance Advisory Group, LLC
unchanged
-
-25,725
251,807
0.06%

1–10 of 48

Are Funds Buying or Selling INCY?

Are funds buying INCY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INCY
No. of Funds

Unveiling Incyte Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
dodge & cox
7.2%
16,090,421
SC 13G/A
Feb 13, 2024
vanguard group inc
10.05%
22,519,381
SC 13G/A
Jan 24, 2024
blackrock inc.
10.8%
24,297,249
SC 13G/A
Dec 08, 2023
vanguard group inc
10.02%
22,466,463
SC 13G/A
Jun 08, 2023
blackrock inc.
10.5%
23,468,952
SC 13G/A
Mar 15, 2023
baker bros. advisors lp
16.3%
36,280,967
SC 13D/A
Feb 14, 2023
dodge & cox
8.7%
19,362,935
SC 13G/A
Feb 09, 2023
vanguard group inc
9.68%
21,533,818
SC 13G/A
Jan 25, 2023
blackrock inc.
8.9%
19,836,617
SC 13G/A
Mar 10, 2022
baker bros. advisors lp
16.4%
36,269,307
SC 13D/A

Recent SEC filings of Incyte Corp

View All Filings
Date Filed Form Type Document
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Mar 27, 2024
3
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 25, 2024
SC 13G
Major Ownership Report
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading

Peers (Alternatives to Incyte Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.0B
6.8B
-2.93% -28.56%
-8.27
5.69
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.3B
1.8B
-2.14% -28.32%
-41.48
9.99
76.23% 61.08%
17.0B
2.4B
5.64% -9.07%
101.38
7.03
15.42% 18.43%
11.9B
3.7B
-9.46% -28.45%
19.84
3.21
8.87% 75.42%
MID-CAP
5.7B
396.6M
-16.55% -42.15%
-10.83
14.44
425.83% 18.94%
4.4B
-
-12.14% 49.76%
-6.72
60.35
54.84% -34.79%
3.1B
270.6M
-14.48% -8.88%
-13.02
11.51
440.80% -27.84%
2.8B
726.4M
-8.72% -14.74%
-45.89
3.87
40.45% 71.62%
2.8B
240.7M
-18.65% -25.84%
-9.43
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-6.41% -11.48%
25.32
4.54
85.90% -14.05%
544.4M
983.7M
-21.26% -56.58%
-1
0.55
-50.36% 17.16%
382.8M
881.7K
-14.69% 262.26%
-8.58
466.16
-77.61% -5.33%
238.4M
4.9M
-4.49% -3.41%
-1.76
48.98
-54.97% 51.71%
6.2M
2.1M
67.92% 36.92%
-0.23
2.14
-13.45% 66.37%

Incyte Corp News

Latest updates
MarketBeat16 hours ago
Nasdaq12 Apr 202408:32 pm
MarketWatch05 Apr 202407:00 am
Seeking Alpha27 Feb 202408:00 am

Incyte Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue10.3%1,013919955809927823911733863813706605790621688569579552530498528
Cost Of Revenue16.1%70.0060.0068.0057.0059.0055.0051.0043.0044.0040.0038.0029.0036.0034.0033.0027.0032.0030.0029.0023.0026.00
Costs and Expenses17.3%8267047617848576856576177525785655066256154571,233484417431424446
  S&GA Expenses9.7%294268284316273266253210226191169154167121118111136103106124108
  R&D Expenses18.3%444376401407501384347353-3353443074064382871,085313281289271-891
EBITDA Margin23.8%0.25*0.20*0.18*0.17*0.18*0.19*0.21*0.20*0.21*0.23*0.17*0.22*---------
Interest Expenses29.1%1.001.001.000.001.001.001.001.001.000.000.000.000.001.001.001.001.001.000.000.000.00
Income Taxes11.7%70.0063.0074.0030.0052.0036.0068.0033.00-44328.0022.0016.0018.0012.0017.0017.0015.0020.003.002.002.00
Earnings Before Taxes15.9%27123427852.0081.0014922971.0012020917269.00168-3.51307-70412614810910471.00
EBT Margin26.5%0.23*0.18*0.16*0.15*0.16*0.17*0.19*0.18*0.19*0.21*0.15*0.20*---------
Net Income17.4%20117120422.0028.0011316138.0056418214954.00150-15.20290-72011112810510269.00
Net Income Margin37.3%0.16*0.12*0.10*0.09*0.10*0.26*0.28*0.30*0.32*0.18*0.12*0.18*---------
Free Cashflow-0.1%148148307-105284296174216115255173206---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets6.2%6,7826,3886,2085,7985,8415,5105,3195,0544,9334,1993,9053,6613,5613,3073,2122,7523,4273,2152,9482,7542,646
  Current Assets5.5%4,6454,4034,2643,9724,0933,8213,6263,2883,1192,9242,6202,4502,3602,1592,0781,7162,4811672,0591,9051,832
    Cash Equivalents-0.4%3,2133,2273,1312,8212,9512,6922,4372,2582,0592,0011,7991,6721,5151,5001,3291,0461,8341,7031,4171,3011,165
  Inventory10.1%63.0057.0036.0041.0042.0046.0055.0035.0028.0021.0017.0017.0016.0017.0016.0014.0011.007.007.007.007.00
  Net PPE2.5%752733749742739716721729724687661595560498454410378347339338320
  Goodwill0%156156156156156156156156156156156156156156156156156156156156156
Liabilities9.3%1,5921,4571,4681,3351,4711,2841,2341,1911,1631,050969934950917868815828792700669720
  Current Liabilities10.3%1,2401,1251,1191,0061,1571,007927886854743660624631606557503513133367365425
  Long Term Debt------------------18.0018.0018.0017.00
    LT Debt, Current--------------12.0019.0019.0018.00----
    LT Debt, Non Current------------------18.0018.0018.0017.00
Shareholder's Equity5.2%5,1904,9314,7414,4634,3704,2274,0853,8633,7703,1492,9362,7282,6112,3912,3451,9382,5982,4232,2472,0861,926
  Retained Earnings494.1%160-40.69-211-415-437-465-578-739-777-1,341-1,523-1,672-1,726-1,876-1,861-2,151-1,430-1,541-1,670-1,775-1,877
  Additional Paid-In Capital1.4%5,0164,9494,9264,8574,7924,7214,6894,6264,5674,5094,4774,4214,3534,2774,2184,1024,0443,9733,9263,8703,814
Shares Outstanding0.1%224224223223223222221221220220220220---------
Float---11,700---14,200---16,000---19,100---15,400--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-0.1%147,729147,835306,526-105,603283,662296,381174,157215,741115,351255,098172,944206,095107,321182,115269,382-683,417131,618270,415152,960155,66383,838
  Share Based Compensation25.0%59,99048,00054,52053,37952,67945,40446,49643,84148,22242,69444,73247,35845,26143,80046,30342,51342,02343,35940,61540,59237,323
Cashflow From Investing-798.8%-154,500-17,189-7,429-28,559-20,912-28,402-12,480-16,748-66,047-32,754-49,145-59,753-102,730-14,453-43,258-108,560-30,02812,284-45,147-24,563-36,097
Cashflow From Financing100.9%346-37,25612,8684,009-2,480-14,31115,90196.009,005-19,3433,67912,83511,87293156,4072,49929,3202,8949,0104,4874,063

INCY Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Total revenues$ 3,695,649$ 3,394,635$ 2,986,267
Costs and expenses:   
Cost of product revenues (including definite-lived intangible amortization)254,990206,997150,991
Research and development1,627,5941,585,9361,458,179
Selling, general and administrative1,161,2931,002,140739,560
Loss on change in fair value of acquisition-related contingent consideration29,20212,14914,741
(Profit) and loss sharing under collaboration agreements2,0457,97337,019
Total costs and expenses3,075,1242,815,1952,400,490
Income from operations620,525579,440585,777
Interest income and other, net172,34839,93210,647
Interest expense(2,551)(2,666)(1,908)
Unrealized gain (loss) on long term investments43,893(87,590)(24,072)
Income before provision (benefit) for income taxes834,215529,116570,444
Provision (benefit) for income taxes236,616188,456(378,137)
Net income$ 597,599$ 340,660$ 948,581
Net income per share:   
Basic (in dollars per share)$ 2.67$ 1.53$ 4.30
Diluted (in dollars per share)$ 2.65$ 1.52$ 4.27
Shares used in computing net income per share:   
Basic (in shares)223,628222,004220,428
Diluted (in shares)225,928223,958222,074
Product revenues, net   
Revenues:   
Total revenues$ 3,165,168$ 2,746,897$ 2,322,012
Product royalty revenues   
Revenues:   
Total revenues523,481482,738569,255
Milestone and contract revenues   
Revenues:   
Total revenues$ 7,000$ 165,000$ 95,000

INCY Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 3,213,376$ 2,951,422
Marketable securities—available-for-sale (amortized cost $442,816 and $292,580 as of December 31, 2023 and 2022 respectively; allowance for credit losses $0 as of December 31, 2023 and 2022)442,667287,543
Accounts receivable743,557644,879
Inventory62,97241,995
Prepaid expenses and other current assets182,830167,011
Total current assets4,645,4024,092,850
Restricted cash1,8451,698
Long term investments187,716133,676
Inventory206,96578,964
Property and equipment, net751,513739,310
Finance lease right-of-use assets, net25,53526,298
Other intangible assets, net123,545129,219
Goodwill155,593155,593
Deferred income tax asset631,886457,941
Other assets, net52,10725,435
Total assets6,782,1075,840,984
Current liabilities:  
Accounts payable109,601277,546
Accrued compensation153,348138,761
Accrued and other current liabilities935,569701,053
Finance lease liabilities3,4393,179
Acquisition-related contingent consideration38,42236,538
Total current liabilities1,240,3791,157,077
Acquisition-related contingent consideration173,578184,462
Finance lease liabilities29,16230,083
Other liabilities149,15199,243
Total liabilities1,592,2701,470,865
Commitments and contingencies (Note 16)
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of December 31, 2023 and 202200
Common stock, $0.001 par value; 400,000,000 shares authorized; 224,286,862 and 222,746,719 shares issued and outstanding as of December 31, 2023 and 2022, respectively224223
Additional paid-in capital5,016,1224,792,041
Accumulated other comprehensive income13,10615,069
Retained earnings (accumulated deficit)160,385(437,214)
Total stockholders’ equity5,189,8374,370,119
Total liabilities and stockholders’ equity$ 6,782,107$ 5,840,984
INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
 CEO
 WEBSITEincyte.com
 INDUSTRYBiotechnology
 EMPLOYEES2324

Incyte Corp Frequently Asked Questions


What is the ticker symbol for Incyte Corp? What does INCY stand for in stocks?

INCY is the stock ticker symbol of Incyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Incyte Corp (INCY)?

As of Thu Apr 18 2024, market cap of Incyte Corp is 11.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INCY stock?

You can check INCY's fair value in chart for subscribers.

What is the fair value of INCY stock?

You can check INCY's fair value in chart for subscribers. The fair value of Incyte Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Incyte Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INCY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Incyte Corp a good stock to buy?

The fair value guage provides a quick view whether INCY is over valued or under valued. Whether Incyte Corp is cheap or expensive depends on the assumptions which impact Incyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INCY.

What is Incyte Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, INCY's PE ratio (Price to Earnings) is 19.84 and Price to Sales (PS) ratio is 3.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INCY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Incyte Corp's stock?

In the past 10 years, Incyte Corp has provided 0.011 (multiply by 100 for percentage) rate of return.